KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Adaptive Biotechnologies (ADPT) EBITDA Margin (2018 - 2025)

Historic EBITDA Margin for Adaptive Biotechnologies (ADPT) over the last 8 years, with Q3 2025 value amounting to 10.95%.

  • Adaptive Biotechnologies' EBITDA Margin rose 417500.0% to 10.95% in Q3 2025 from the same period last year, while for Sep 2025 it was 23.43%, marking a year-over-year increase of 509500.0%. This contributed to the annual value of 90.83% for FY2024, which is 425000.0% up from last year.
  • According to the latest figures from Q3 2025, Adaptive Biotechnologies' EBITDA Margin is 10.95%, which was up 417500.0% from 10.31% recorded in Q2 2025.
  • Adaptive Biotechnologies' 5-year EBITDA Margin high stood at 10.95% for Q3 2025, and its period low was 322.32% during Q2 2023.
  • Moreover, its 5-year median value for EBITDA Margin was 94.98% (2022), whereas its average is 100.72%.
  • In the last 5 years, Adaptive Biotechnologies' EBITDA Margin crashed by -2020700bps in 2023 and then surged by 2799000bps in 2024.
  • Quarter analysis of 5 years shows Adaptive Biotechnologies' EBITDA Margin stood at 162.39% in 2021, then skyrocketed by 56bps to 70.99% in 2022, then plummeted by -119bps to 155.22% in 2023, then soared by 54bps to 71.3% in 2024, then skyrocketed by 115bps to 10.95% in 2025.
  • Its EBITDA Margin was 10.95% in Q3 2025, compared to 10.31% in Q2 2025 and 56.45% in Q1 2025.